ALTEOGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 193,100 KRW | +3.87% |
|
+1.85% | +96.04% |
| 2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
| 2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 929,693 | 5,046,497 | 3,198,722 | 1,970,174 | 5,137,836 | 10,258,403 | - | - |
| Enterprise Value (EV) 2 | 872 | 5,011 | 2,999 | 1,847 | 5,053 | 10,222 | 10,199 | 9,776 |
| P/E ratio | - | -5,134 x | -433 x | -241 x | -1,515 x | 1,430 x | 201 x | 23.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 31.7 x | 119 x | 77.8 x | 68.4 x | 53.2 x | 130 x | 60.5 x | 18.6 x |
| EV / Revenue | 29.7 x | 118 x | 72.9 x | 64.1 x | 52.4 x | 130 x | 60.1 x | 17.7 x |
| EV / EBITDA | -681 x | 2,540 x | -282 x | -69.1 x | -789 x | 881 x | 129 x | 23.3 x |
| EV / FCF | 899 x | -1,456 x | -99.3 x | -76 x | -562 x | 1,043 x | 194 x | 25.7 x |
| FCF Yield | 0.11% | -0.07% | -1.01% | -1.32% | -0.18% | 0.1% | 0.52% | 3.89% |
| Price to Book | 12.8 x | 38.5 x | 23.4 x | 13.2 x | 34.2 x | 65.9 x | 46.6 x | 16.6 x |
| Nbr of stocks (in thousands) | 50,028 | 50,549 | 50,706 | 51,508 | 52,161 | 53,125 | - | - |
| Reference price 3 | 18,583 | 99,833 | 63,083 | 38,250 | 98,500 | 193,100 | 193,100 | 193,100 |
| Announcement Date | 20-02-12 | 21-03-10 | 22-03-11 | 23-03-13 | 24-03-11 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 29.37 | 42.43 | 41.12 | 28.81 | 96.52 | 78.73 | 169.6 | 552.6 |
| EBITDA 1 | -1.28 | 1.973 | -10.64 | -26.72 | -6.403 | 11.6 | 79.03 | 418.8 |
| EBIT 1 | -2.252 | 0.1037 | -12.63 | -29.37 | -9.737 | 9.6 | 76.8 | 417.5 |
| Operating Margin | -7.67% | 0.24% | -30.72% | -101.97% | -10.09% | 12.19% | 45.27% | 75.55% |
| Earnings before Tax (EBT) 1 | - | -2.839 | -6.885 | -9.97 | -3.564 | 8 | 69 | 442.3 |
| Net income 1 | - | -0.9696 | -7.383 | -8.146 | -3.372 | 7.2 | 50 | 437.3 |
| Net margin | - | -2.29% | -17.95% | -28.28% | -3.49% | 9.14% | 29.48% | 79.13% |
| EPS 2 | - | -19.44 | -145.8 | -159.0 | -65.00 | 135.0 | 961.3 | 8,249 |
| Free Cash Flow 3 | 969.6 | -3,442 | -30,198 | -24,298 | -8,985 | 9,800 | 52,600 | 379,800 |
| FCF margin | 3,301.93% | -8,113.61% | -73,432.95% | -84,349.5% | -9,308.55% | 12,447.08% | 31,008.06% | 68,729.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 84,482.76% | 66,554.2% | 90,687.68% |
| FCF Conversion (Net income) | - | - | - | - | - | 136,111.11% | 105,200% | 86,851.13% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-12 | 21-03-10 | 22-03-11 | 23-03-13 | 24-03-11 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 |
|---|---|---|
| Net sales 1 | - | 10.52 |
| EBITDA | - | - |
| EBIT 1 | - | -2.756 |
| Operating Margin | - | -26.18% |
| Earnings before Tax (EBT) 1 | - | -3.213 |
| Net income 1 | -6.151 | -2.188 |
| Net margin | - | -20.79% |
| EPS | -143.0 | - |
| Dividend per Share | - | - |
| Announcement Date | 22-11-11 | 23-03-13 |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 57.7 | 35.2 | 199 | 123 | 84.8 | 36.8 | 59.2 | 483 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | 970 | -3,442 | -30,198 | -24,298 | -8,985 | 9,800 | 52,600 | 379,800 |
| ROE (net income / shareholders' equity) | -0.96% | -3.31% | -4.01% | -7.22% | -2.44% | 4.7% | 24.1% | 110% |
| ROA (Net income/ Total Assets) | -0.84% | -2.79% | -3.51% | -3.23% | -1.34% | 3.2% | 12.5% | 55.8% |
| Assets 1 | - | 34.75 | 210.5 | 251.9 | 250.8 | 225 | 400 | 783.7 |
| Book Value Per Share 3 | 1,452 | 2,594 | 2,702 | 2,889 | 2,876 | 2,929 | 4,144 | 11,649 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 8.16 | 5.12 | 13.6 | 6.42 | 1.22 | 1.33 | - | - |
| Capex / Sales | 27.8% | 12.07% | 33.04% | 22.3% | 1.26% | 1.69% | - | - |
| Announcement Date | 20-02-12 | 21-03-10 | 22-03-11 | 23-03-13 | 24-03-11 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
193,100
KRW
Average target price
246,667
KRW
Spread / Average Target
+27.74%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +96.04% | 7.49B | |
| -2.21% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.86% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +4.94% | 8.94B |
- Stock Market
- Equities
- A196170 Stock
- Financials ALTEOGEN Inc.
